Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2019

View Archived Issues

First patient dosed in phase II study of IMB-115

18F-Labeled PSMA ligand development leads to clinical candidate [18F]siPSMA-14

Brain axonal iron transport modulates anxiety-related behaviors

Enhancing PGK1 activity and increasing glycolysis may slow neurodegeneration in Parkinson's disease

SCO-792, a novel small-molecule enteropeptidase inhibitor blocking protein digestion in vivo

Dosing begins in NIH-funded phase II proof-of-concept study of ANS-6637

Interim data reported from BRIDGE phase III study of pegunigalsidase alpha in Fabry disease

Phase III BE VIVID study of bimekizumab in psoriasis meets all endpoints

Syros discontinues SY-1365 and focuses on the development of SY-5609

Topline results presented from first cohort of phase II study of low-dose inarigivir plus Vemlidy

First-in-human data presented for [99mTc]-ADAPT6

Bioevaluation of novel TSPO-selective PET probe, [18F]BS-224

Synthesis and characterization of novel N-carboxymethyl-substituted PSMA ligands

Medshine Discovery presents new dual SGLT1 and SGLT2 inhibitors

New FGFR inhibitors described by the Shanghai Institute of Organic Chemistry

Shanghai Meiyue Biotech Development discovers thrombin and factor XIa inhibitors

New apoptosis regulator Bcl-2 inhibitors disclosed by Jiangsu Chia Tai Tianqing Pharmaceutical Group

Shanghai Institute of Materia Medica and Jinan University patent AXL and/or FLT3 inhibitors

TAP downregulation by an aptamer-siRNA conjugate could potentiate responsiveness to immune therapy

New potent and selective ROS1/TRK family inhibitor is effective in crizotinib-resistant models

Novel albumin-binding agents for FAP-targeted radionuclide therapy presented

FDA approves Xofluza to treat influenza in those at high risk of influenza complications

Spring Bank initiates phase I study of SB-11285 alone and with nivolumab in solid tumors

SHARPIN gene variant linked to late-onset Alzheimer's disease in Japanese subjects

Scientists tie novel genetic variant in RBMX2 gene to bipolar disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...